Cougar Biotechnology Announces Presentation Of Positive Preclinical Data Or CB3304 In Non-Hodgkin's Lymphoma And Multiple Myeloma

LOS ANGELES--(BUSINESS WIRE)--Dec. 13, 2005--Cougar Biotechnology, Inc., a privately held biotechnology company, today announced the presentation of results from preclinical experiments that demonstrate the effectiveness of the Company's drug CB3304 (noscapine) for the treatment of non-Hodgkin's lymphoma and multiple myeloma. The data was presented as a poster presentation at the American Society of Hematology Annual Meeting in Atlanta, Georgia.